<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527838</url>
  </required_header>
  <id_info>
    <org_study_id>FT1050-02</org_study_id>
    <nct_id>NCT01527838</nct_id>
  </id_info>
  <brief_title>Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit</brief_title>
  <official_title>A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a prospective, open-label, single-arm trial of the safety of a single&#xD;
      FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity&#xD;
      conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects&#xD;
      will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in three sequential cohorts of 6-12 evaluable subjects each.&#xD;
&#xD;
      Cohort 1 will enroll eligible subjects for whom a single CB unit has been identified that&#xD;
      meets the minimum HLA-matching criteria and has a minimum pre-cryopreservation total&#xD;
      nucleated cell (TNC) dose of at least 2.5 x 10^7 cells/kg. Cohort 2 is identical to Cohort 1,&#xD;
      except that the TNC dose of the CB unit must be between 2.0 - &lt;2.5 x 10^7 cells/kg. Finally,&#xD;
      Cohort 3 is identical to Cohort 2, except that the TNC dose of the CB unit must be between&#xD;
      1.5 - &lt;2.0 x 10^7 cells/kg. If no safety rules are triggered, the study will proceed to the&#xD;
      next dosing cohort. Within a dosing cohort, no more than three subjects may be before Day 42&#xD;
      at any one time, unless they have already engrafted neutrophils. The final dosing cohort is&#xD;
      defined as the last cohort where 12 evaluable subjects are treated and no stopping rules are&#xD;
      triggered. The corresponding TNC dose level will be considered the minimally acceptable TNC&#xD;
      dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil engraftment/chimerism</measure>
    <time_frame>Day 42</time_frame>
    <description>To determine the minimally effective TNC dose for a single FT1050-treated CB unit based on neutrophil engraftment/chimerism when used for hematopoietic reconstitution following a reduced-intensity conditioning regimen for hematologic malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Day 100</time_frame>
    <description>Define the safety profile of treatment with a single FT1050-treated CB unit. To define the preliminary efficacy of treatment with a single FT1050-treated CB unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>2 years</time_frame>
    <description>To assess immune reconstitution (B-, T-, and NK-cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor search</measure>
    <time_frame>Day 0</time_frame>
    <description>To determine time from the initiation of donor search to transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>Single FT1050 treated UCB Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single FT1050 treated UCB unit</intervention_name>
    <description>Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood</description>
    <arm_group_label>Single FT1050 treated UCB Unit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with hematologic malignancies for whom allogeneic stem cell transplantation&#xD;
             is deemed clinically appropriate. Eligible diseases and stages include:&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma or Hodgkin's lymphoma&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML)&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
          2. Lack of 5-6/6 HLA-matched related or 8/8 HLA-A, B, C, DRß1 matched unrelated donor; or&#xD;
             unrelated donor not available within appropriate timeframe.&#xD;
&#xD;
               -  Identification of suitable backup CB unit(s) (single unit with&#xD;
                  pre-cryopreservation cell dose ≥ 2.5 x 10^7 TNC/kg or two units with&#xD;
                  pre-cryopreservation cell dose ≥ 1.5 x 10^7 TNC/kg each) and meeting minimum HLA&#xD;
                  match criteria.&#xD;
&#xD;
               -  An acceptable alternative to one or two backup CB unit(s) is the identification&#xD;
                  of an eligible related haploidentical donor that meets minimum HLA match&#xD;
                  criteria.&#xD;
&#xD;
          3. Age 18-65 years.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
          5. Signed IRB approved Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The following hematologic malignancies are excluded:&#xD;
&#xD;
               -  Myelofibrosis (Agnogenic Myeloid Metaplasia)&#xD;
&#xD;
               -  Aplastic anemia.&#xD;
&#xD;
          2. Previous treatment that included an allogeneic transplant&#xD;
&#xD;
          3. Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular&#xD;
&#xD;
          4. dysfunction (Ejection fraction &lt; 40%) as measured by gated radionucleotide&#xD;
             ventriculogram or echocardiogram; active angina pectoris, or uncontrolled&#xD;
             hypertension; history of myocardial infarction with depressed ejection fraction.&#xD;
&#xD;
          5. Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic&#xD;
             restrictive lung disease, or corrected DLCO of &lt; 50% of predicted, corrected for&#xD;
             hemoglobin.&#xD;
&#xD;
          6. Renal disease: serum creatinine &gt; 2.0 mg/dl and calculated creatinine clearance &lt; 40&#xD;
             mL/min&#xD;
&#xD;
          7. Hepatic disease: serum bilirubin &gt; 2.0 mg/dl (except in the case of Gilbert's syndrome&#xD;
             or ongoing hemolytic anemia), SGOT or SGPT &gt; 3 x upper limit of normal.&#xD;
&#xD;
          8. Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other&#xD;
             neuropsychiatric abnormalities believed to preclude transplantation.&#xD;
&#xD;
          9. HIV antibody.&#xD;
&#xD;
         10. Uncontrolled infection.&#xD;
&#xD;
         11. Pregnancy or breast feeding mother.&#xD;
&#xD;
         12. Inability to comply with the requirements for care after allogeneic stem cell&#xD;
             transplantation.&#xD;
&#xD;
         13. Participation in a concurrent clinical trial with a novel, unapproved investigational&#xD;
             agent &lt; 30 days prior to Day 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Dychter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univeristy Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

